anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metastasis is a complex, multistep process. To study the molecular steps of the metastatic cascade, it is important to use an in vivo system that recapitulates the complex tumor microenvironment. The chicken embryo chorioallantoic membrane (CAM) is an in vivo system suitable for the implantation of xenograft tumor models. It allows the study of different aspects of the metastatic process, including the dormancy-awakening transition. The main advantages of this system are its high reproducibility, cost-effectiveness, and versatility. Here, by using two dormancy tumor models, one of head and neck squamous cell carcinoma and one of breast cancer, we described a detailed protocol for the use of the CAM model in metastasis assays and for the study of tumor growth and dormancy.
Heart rhythm biofeedback is a non-invasive physiological treatment that is administered via an app downloaded to personal smart phones. It involves participants attaching a wireless sensor to the ear that monitors heart rate that is displayed on the phone screen app. The participant is actively involved in modifying the heart biofeedback to achieve optimal levels of heart rate variability, an established indicator of health and well-being and a potential factor in chronic fatigue syndrome. The treatment lasts 8 weeks.
The present invention refers to nucleic acid aptamers comprising a nucleotides sequence with general formula (1), as follows, or a pharmaceutical acceptable salt thereof: TAGGGAAGAGAAGGACATATGAT-X1-TTGACTAGTACATGACCAC TTGA (formula 1), wherein X1 is the nucleotides sequence as defined in any one of the SEQ ID NO: 1 - 10, SEQ ID NO: 21 - 30 e SEQ ID NO: 41 - 50, or a sequence with at least 90 % identity to the same which presents a function equivalent to its corresponding. The present invention further refers to the composition comprising at least one aptamer as previously defined. The present invention further refers to the use of an aptamer as previously defined or a composition as previously defined for the manufacture of a drug for the treatment of cancer. The present invention further refers to the diagnostic kit comprising the aptamers as previously defined or the composition as previously defined. The present invention further refers to the method for detecting or diagnosing a tumor, which comprises contacting at least one aptamer as previously defined or a composition as previously defined with a cell, tissue, or sample from an individual, and detecting the binding of the aptamer to the cell, tissue, or sample. The present invention further refers to a method for treating cancer, comprising a step of administering to an individual a therapeutically effective amount of an aptamer as previously defined or of a composition as previously defined.
Pituitary apoplexy: During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed, with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.

Cardiovascular adverse events: Cases of serious venous and arterial thromboembolism have been reported, including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and transient ischemic attack. Although a temporal relationship was reported in some cases, most cases were confounded by risk factors or concomitant medication use. It is unknown if there is a causal association between the use of GnRH analogs and these events.

Central/peripheral nervous adverse events: Convulsion.

Psychiatric adverse events: Mood swings, including depression; suicidal ideation and attempt.

Hepatic adverse events: Rarely reported serious liver injury.

Reproductive system adverse events: Cases of ovarian hyperstimulation syndrome have been reported with Synarel monotherapy when used for Assisted Reproductive Technology which is not an approved indication.
Herein are described pharmabiotic compositions and methods of treatment using genetically modified bacteria that include a portion or a variant of human cDNA sequence. Generally, the modified bacterium has a genetic modification that includes the introduction or inclusion of non-native DNA which contain a human cDNA sequence that can be propagated in the genetically altered bacterium. As an example, the non-native DNA can include one or more portions of human cDNA that encode the enzyme phenylalanine hydroxylase. In an embodiment, the modified bacterium can be provided to a patient as a treatment for a metabolic disorder. In a non-limiting example, a modified bacterium including human cDNA encoding the enzyme phenylalanine hydroxylase can be provided to a patient suffering from a deficiency in phenylalanine hydroxylase or suffering from a mutation to the native gene that results in an inactive form of the enzyme. As such, certain embodiments may provide methods for treating phenylketonuria using the modified bacterium.
BACKGROUND: Progressive supranuclear palsy (PSP) is a tauopathy that involves subcortical regions but also extends to cortical areas. The clinical impact of different tau protein sites and their influence on glymphatic dysfunction have not been investigated.
PATIENTS AND METHODS: Participants (n = 55; 65.6 ± 7.1 years; 29 women) with PSP (n = 32) and age-matched normal controls (NCs; n = 23) underwent 18 F-Florzolotau tau PET, MRI, PSP Rating Scale (PSPRS), and Mini-Mental State Examination. Cerebellar gray matter (GM) and parametric estimation of reference signal intensity were used as references for tau burden measured by SUV ratios. Glymphatic activity was measured by diffusion tensor image analysis along the perivascular space (DTI-ALPS).
RESULTS: Parametric estimation of reference signal intensity is a better reference than cerebellar GM to distinguish tau burden between PSP and NCs. PSP patients showed higher cortical and subcortical tau SUV ratios than NCs ( P < 0.001 and <0.001). Cortical and subcortical tau deposition correlated with PSPRS, UPDRS, and Mini-Mental State Examination scores (all P 's < 0.05). Cortical tau deposition was further associated with the DTI-ALPS index and frontal-temporal-parietal GM atrophy. The DTI-ALPS indexes showed a significantly negative correlation with the PSPRS total scores ( P < 0.01). Finally, parietal and occipital lobe tau depositions showed mediating effects between the DTI-ALPS index and PSPRS score.
CONCLUSIONS: Cortical tau deposition is associated with glymphatic dysfunction and plays a role in mediating glymphatic dysfunction and clinical severity. Our results provide a possible explanation for the worsening of clinical severity in patients with PSP.
Expansion cohorts of monotherapy BM230 in multiple dose levels after evaluation for safety in Monotherapy Dose Escalation arm. Additional pharmacokinetic (PK) and pharmacodynamic (PD) samples included in this arm.
Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
OBJECTIVE: Klebsiella pneumoniae are common pathogens causing bloodstream infection (BSI) that increasingly express carbapenem resistance worldwide. To date, no study has precisely investigated the impact of carbapenem resistance in K. pneumoniae (CRKP) BSI on mortality.
METHODS: This retrospective study included 87 patients with CRKP BSI and 321 patients with carbapenem-susceptible K. pneumoniae (CSKP) BSI from 2015 to 2020. Propensity score analyses with stabilized inverse probability of treatment weighting (IPTW-S) was applied to balance covariates. The hazard ratio for 30-day mortality associated with carbapenem resistance was estimated using Cox regression and Kaplan-Meier curves.
RESULTS: The 30-day crude mortality rates were 43.7% in patients with CRKP BSI and 17.8% in patients with CSKP BSI (P < .001). Age ≥55 years, underlying hematological malignancies and hemodialysis were independently associated with mortality in CRKP BSI. A skin or soft-tissue infection source, urinary catheter, and underlying chronic obstructive pulmonary disease were predictors of mortality in CSKP BSI. The group characteristics were well balanced after IPTW-S. The adjusted hazard ratio for 30-day mortality for CRKP BSI was 1.607 (interquartile range, 0.814-3.171).
CONCLUSIONS: Carbapenem resistance was not associated with a significant increase in 30-day mortality in KP BSI; patient and disease factors were primary determinants of outcomes.
Smartphone apps may be useful to guide and support individuals in self-management strategies. Primary dysmenorrhea is a very common problem for women. With a randomized, pragmatic study the investigators aim to evaluate whether a smartphone app for women with menstrual pain is effective in reducing menstrual pain in 18-34-year-old women with primary dysmenorrhea. For this the investigators compare the complete smartphone app with two control versions of this app. The complete app provides evidence-based self-care information and instructions for self-acupressure in menstrual pain, the control intervention I includes self-care information, but no instructions for self-acupressure, and control intervention II includes instructions for self-acupressure, but no self-care information. The investigators aim to observe 594 women with primary dysmenorrhea over 12 menstruation cycles. The primary outcome is the mean pain intensity on the days with pain during the 6th menstruation after randomization using a numerical rating scale (NRS; 0=no pain; 10=strongest pain imaginable). Women are eligible when they suffer from primary dysmenorrhea, are between 18 and 34 years old, not pregnant and do not plan to be pregnant within the next 12 months.
PURPOSE: A cognitive ability training apparatus using a robot and a cognitive ability evaluation method thereof are provided to give a cognitive treatment in a three-dimensional real space by delivering instruction through a robot and perform various cognitive treatments utilizing the whole body of a patient. CONSTITUTION: A cognitive ability training apparatus(100) includes an instruction generating unit(110), a sensor unit(120), a trainee action information generating unit(140), and a cognitive ability determining unit(150). The instruction generating unit generates a series of robot instruction information to indicate the action of a robot and a series of trainee instruction information to indicate the action of a trainee. The sensor unit copies the action of the robot following the robot instruction information or collects sensor information including three-dimensional location information, color information, or mobile device usage information of the trainee action following the trainee instruction information. The trainee action information generating unit generates trainee action information based on sensor information collected by the sensor unit. The cognitive ability determining unit determines the cognitive ability of the trainee based on the robot instruction information, the trainee instruction information, and the trainee action information. [Reference numerals] (110) Instruction generating unit; (120) Sensor unit; (130) Trainee information managing unit; (140) Trainee action information generating unit; (150) Cognitive ability determining unit; (160) Display unit; (170) Voice unit; (180) First communication unit; (190) Robot instruction DB; (191) Trainee information DB; (192) Action information DB;
Control patients will be submitted to 3 cycles of sham RIPC. Each cycle of Sham RIPC consists of a pseudo ischemia of the left upper limb caused by inflating a blood pressure cuff to 20mmHg for 5 minutes followed by 5 minutes of reperfusion time.
PURPOSE:To obtain the subject agent useful for the prevention and remedy of transient ischemic attack, microangiopathic hemolytic syndrome, arteriosclerosis, myocardial infarction, etc., by using S-(1,2-dicarboxyethyl)glutathione or its salt as an active component. CONSTITUTION:The subject agent contains the compound of formula or its salt (e.g. the carboxyl group is converted to Na salt or Ca salt or the amino group is converted to the salt of an inorganic acid or organic acid) as an active component. Since the compound of formula is a peptide existing in living body such as yeast or bovine lens, it has high safety. The agent can be applied also as a remedy for diseases accompanying vascular permeability promotion in inflammation or abnormal proliferation of connective tissue. The daily dose of the agent for adult is preferably 20-400mg for injection or 50-800mg for oral administration.
The efficacy of KEYTRUDA in combination with gemcitabine and cisplatin chemotherapy was investigated in KEYNOTE-966 (NCT04003636), a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 1069 patients with locally advanced unresectable or metastatic BTC, who had not received prior systemic therapy in the advanced disease setting. Patients with autoimmune disease that required systemic therapy within 2 years of treatment or a medical condition that required immunosuppression were ineligible. Randomization was stratified by region (Asia vs. non-Asia), locally advanced versus metastatic, and site of origin (gallbladder, intrahepatic or extrahepatic cholangiocarcinoma).

Patients were randomized (1:1) to KEYTRUDA 200 mg on Day 1 plus gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Day 1 and Day 8 every 3 weeks, or placebo on Day 1 plus gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Day 1 and Day 8 every 3 weeks. Study medications were administered via intravenous infusion. Treatment continued until unacceptable toxicity or disease progression. For pembrolizumab, treatment continued for a maximum of 35 cycles, or approximately 24 months. For gemcitabine, treatment could be continued beyond 8 cycles while for cisplatin, treatment could be administered for a maximum of 8 cycles.

Administration of KEYTRUDA with chemotherapy was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. Assessment of tumor status was performed at baseline and then every 6 weeks through 54 weeks, followed by every 12 weeks thereafter.

Study population characteristics were median age of 64 years (range: 23 to 85), 47% age 65 or older; 52% male; 49% White, 46% Asian, 1.3% Black or African American; 10% Hispanic or Latino; 46% ECOG PS of 0 and 54% ECOG PS of 1; 31% of patients had a history of hepatitis B infection, and 3% had a history of hepatitis C infection.

The major efficacy outcome measure was OS. Additional efficacy outcome measures were PFS, ORR and DoR as assessed by BICR according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Table 91 and Figure 27 summarize the efficacy results for KEYNOTE-966.
Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
A sunscreen applicator system for conveniently storing and dispensing various types of sunscreen lotion within a convenient compact structure. The inventive device includes at least one packaging, a towel sealed within the packaging containing sunscreen lotion, a container for storing at least one packaging, and a storage case for receiving a storing a plurality of containers. Each of the containers and packaging contains an SPF indicia indicating the SPF level of the sunscreen lotion within the packaging. A diverse selection of SPF levels are provided by all of the containers for allowing the user to select from. If the user desires, an individual packaging may be positioned within their wallet, purse or other storage area for later use during the day. The storage case includes a plurality of sides, a floor, an upper opening and a cover pivotally attached to one of the sides. The storage case preferably includes a partition member above the floor of the storage case for creating a waste reservoir wherein a disposal slot extends into said storage case connecting to the waste reservoir for allowing an individual to insert waste material into the waste reservoir.
Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
FIELD: cosmetology. SUBSTANCE: the present innovation deals with special preparations and ways for taking care of fading skin at decreased turgor. The suggested method deals with the following: deeply purified skin of face and neck is successively affected with stimulating gel, followed by conducting massage by applying massage cream and usage of stimulating mask, moreover, stimulating gel, massage cream and stimulating cosmetic mask contain hydrolyzate of wheat proteins and extract of sea algae as the main active substance, and before the impact by stimulating gel, before and after applying a stimulating mask it is necessary to apply an activator onto skin surface that is capable to transfer molecular oxygen. The method enables to improve facial color, the state of skin and provides disappearance of small wrinkles. EFFECT: higher efficiency. 1 ex
Balance and deficit in walking are some of the main characteristics of aging and are considered among the risk factors for falls. Falls are a risk factor for future falls and are associated with other adverse health outcomes such as fear of falling or fractures. In particular, hip fracture in aged patients is an important health problem. In fact, one in three patients dies within the first year after injury, while survivors have poor quality of life For this reason, the development of prevention tools and innovative strategies in the rehabilitation field should be one of the main objectives in the treatment of the diseases afflicting the elderly, such as hip fractures. Effective interventions to promote hip recovery post hip fracture are characterized by intensive and repetitive movements. One treatment approach to increase number of steps during rehabilitation sessions and to improve the balance and the endurance of the patients is the use of robotic systems.

This study is a randomized controlled trial. A total of 195 patients with hip fractures will be recruited and randomly divided into three groups, to receive a traditional rehabilitation program or a robotic rehabilitation in addition to the traditional therapy. Assessments will be performed at baseline, at the end of treatment and 6 months, 1 year and 2 years from the end of the treatment. For the study, post-hospitalization subjects will be taken into consideration, after four weeks from the hospitalization. A 20 treatment sessions will be conducted, divided into 3 training sessions per week, for 7 weeks. The control group will perform traditional therapy sessions lasting 50 minutes. The technological intervention group will carry out 30 minutes of traditional therapy and 20 minutes of treatment with a robotic system.
Blood hemoglobin concentration is a very common and essential test to assess patient well being and the need for blood transfusion. In the perioperative period this measurement is further more critical mainly due to the acute nature of blood loss and the need for an immediate response. Currently, hemoglobin concentration is determined by analyzing a blood sample. It requires venipuncture or arterial puncture (via an arterial line). Besides the patient discomfort there are additional disadvantages such as infection, dealing with blood product, delay with diagnosis, low update rate and cost. Masimo Labs is in the process of developing a noninvasive monitor to detect hemoglobin concentrations in real time. The monitor uses a probe placed on the patient finger that gives hemoglobin concentration continuously and noninvasively. Masimo Labs is using a technology that resembles the well accepted and clinically proven pulse-oxymeter.

The study will include surgical patients at the UCI Medical Center, preferably in cases that are known to involve major blood loss. For these cases, the anesthesia team places an arterial line for anesthesia purposes. The arterial line is used for continuous blood pressure measurements and blood draw for the assessment of several indices. We plan to compare the hemoglobin concentrations measured from blood samples to the Masimo Labs pulse-hemoglobin level readings.
A lottery ticket dispensing system includes a cabinet housing and a lottery ticket array insertable into the cabinet housing. The array includes a plurality of individual bins in a stacked configuration. A dispensing unit is inserted into each of the bins and an automatic separation module in which a leading ticket of a continuous strip of lottery tickets is automatically separated and dispensed from the bin. The lottery ticket array is insertable into and removable from the cabinet housing as a single unit. A stacked configuration of the bins has opposite sides defined by the sides of the bins. At least one first component of a detachable support system is attached to the opposite sides of the stacked configuration, the first component cooperating with a second component of the detachable support system provided on inner side walls of the cabinet housing.
The present invention relates to a medication intake analyzer. An example method for medication intake analysis and reporting. The method includes obtaining a medication order including identification of a medication and a property associated with the medication, where the medication order is associated with a patient. The method includes obtaining a value representing a characteristic of a physical state of the patient, where the value is measured by a sensor in contact with the patient. The method includes determining whether the patient has taken the medication associated with the medication order based on a comparison of the value representing a characteristic of the physical state of the patient. The method includes reporting whether the patient has taken the medication associated with the medication order via a user interface.
PURPOSE:To provide a dermatic agent for external use, containing one or more kinds of iridaceous plant, its extract liquid and extracted component as active components, effective to improve the chapped skin and having excellent aging preventive effect to prevent the sagging of the skin and the loss of the skin luster. CONSTITUTION:An iridaceous plant (e.g. Iris florentina, Iris germanica, etc.), its extract liquid or its extracted component is compounded to an external dermatic agent. The amount of the iridaceous plant is preferably 0.01-1wt% as dried powder of the plant or 0.01-0.1wt% in the case of the extract liquid or extracted component in terms of dried residue. Remarkable effect to prevent the roughening of the skin, to improve the chapped skin and to prevent the aging of the skin can be attained compared with conventional dermatic agent for external use. The effect is especially remarkable when L-ascorbic acid or its ester is compounded to the agent.